健脾益肠散对TNF-α诱导的树突状细胞自噬相关蛋白及基因表达的影响OA
Effect of Jianpi Yichang San on the Expression of Autophagy-Related Proteins and Genes in TNF-α-Induced Dendritic Cells
目的 观察健脾益肠散对肿瘤坏死因子α(TNF-α)诱导的树突状细胞(DCs)自噬相关蛋白及基因表达的影响.方法 将树突状细胞分为正常组(树突状细胞专用培养液)、模型组(TNF-α)、阴性对照组(TNF-α+空白血清)、阳性药组(TNF-α+柳氮磺吡啶血清)、受试药组(TNF-α+健脾益肠散血清)、抑制剂组[TNF-α+3-甲基腺嘌呤(3-MA)5 mmoL·L-1]、激活剂组[TNF-α+雷帕霉素(RAPA)1 μmoL·L-1]、抑制剂+受试药组[TNF-α+3-MA 5 mmoL·L-1+健脾益肠散血清]、激活剂+受试药组[TNF-α+RAPA 1 μmoL·L-1+健脾益肠散血清].正常组细胞用专用培养液处理 24 h;其他组用 10 ng·mL-1 TNF-α诱导构建炎症模型后,含药血清组均加入 10%含药血清处理 24 h,抑制剂组和激活剂组分别给予 3-MA、RAPA处理 24 h.用细胞增殖检测试剂盒(CCK-8)法检测细胞增殖能力,免疫荧光检测自噬相关分子肌球蛋白样BCL2 结合蛋白(Beclin-1)、微管相关蛋白1轻链3-Ⅱ(LC3-Ⅱ)阳性表达,蛋白免疫印迹法(Western Blot)检测树突状细胞 Beclin-1、LC3-Ⅱ、泛素结合蛋白 62(p62/SQSTM1)、自噬蛋白 5(Atg5)、自噬蛋白 7(Atg7)蛋白表达,实时荧光定量聚合酶链式反应(Rt-PCR)法检测p62/SQSTM1、Atg5、Atg7 mRNA表达.结果 与正常组比较,模型组细胞增殖能力明显下降(P<0.01),模型组细胞Beclin-1、LC3-Ⅱ、Atg5、Atg7 蛋白及Atg5、Atg7 mRNA表达明显降低(P<0.01),p62/SQSTM1 蛋白及基因表达明显升高(P<0.01).与模型组比较,受试药组明显增强了细胞增殖能力(P<0.01),并明显上调了Beclin-1、LC3-Ⅱ、Atg5、Atg7 指标的表达(P<0.01),下调了p62/SQSTM1 的表达(P<0.01);抑制剂+受试药组逆转了 3-MA干预下上述指标的异常表达(P<0.01);激活剂+受试药组与RAPA发挥协同作用,进一步上调了上述指标的表达(P<0.01).结论 健脾益肠散对TNF-α诱导的树突状细胞自噬相关蛋白及基因表达具有增强作用,可以促进自噬,这可能是其调控肠道免疫耐受、缓解溃疡性结肠炎炎症的机制之一.
Objective To observe the effect of Jianpi Yichang San(JPYCS)on the expression of autophagy-related proteins and genes in tumor necrosis factor-α(TNF-α)-induced dendritic cells(DCs).Methods Dendritic cells were divided into the following groups:normal group(treated with DC-specific culture medium),model group(treated with TNF-α),negative control group(TNF-α+blank serum),positive drug group(TNF-α+sulfasalazine serum),test drug group(TNF-α+JPYCS serum),inhibitor group[TNF-α+3-methyladenine(3-MA,5 mmol·L-1)],activator group[TNF-α+rapamycin(RAPA,1 μmol·L-1)],inhibitor+test drug group(TNF-α+3-MA 5 mmoL·L-1+JPYCS serum),and activator+test drug group(TNF-α+RAPA 1moL·L-1+JPYCS serum).Cells in the normal group were treated with specific medium for 24 hours.For other groups,an inflammatory model was established by induction with 10 ng·mL-1 TNF-α;then,serum groups were treated with 10%corresponding medicated serum for 24 hours,while the inhibitor and activator groups were treated with 3-MA or RAPA,respectively,for 24 hrous.Cell proliferation was assessed using the Cell Counting Kit-8(CCK-8)assay.Positive expression of autophagy-related myosin-like BCL2 interacting protein and microtubule-associated protein 1 light chain 3-Ⅱ(LC3-Ⅱ)was detected by immunofluorescence.Protein expression of Beclin-1,LC3-Ⅱ,Ubiquitin-binding protein62(p62/SQSTM1),autophagy-related protein 5(Atg5),and autophagy-related protein 7(Atg7)in DCs was determined by Western Blot.mRNA expression of p62/SQSTM1,Atg5,and Atg7 was measured by real-time quantitative polymerase chain reaction(Real-time PCR).Results Compared with the normal group,the model group showed significantly decreased cell proliferation capacity(P<0.01).Protein expression of Beclin-1,LC3-Ⅱ,Atg5,and Atg7,as well as mRNA expression of Atg5 and Atg7,were significantly reduced(P<0.01)in the model group,while protein and gene expression of p62 were significantly increased(P<0.01).The test drug group significantly enhanced cell proliferation capacity(P<0.01),upregulated the expression of Beclin-1,LC3-Ⅱ,Atg5,and Atg7(P<0.01),and downregulated the expression of p62(P<0.01).The inhibitor+test drug group reversed the abnormal expression of the aforementioned indicators under 3-MA intervention(P<0.01).The activator+test drug group exerted a synergistic effect with RAPA,further upregulating the expression of these indicators(P<0.01).Conclusion Jianpi Yichang San enhances the expression of autophagy-related proteins and genes in TNF-α-induced dendritic cells,promoting autophagy.This may be one of its mechanisms for regulating intestinal immune tolerance and alleviating UC inflammation.
罗沛文;刘子龙;罗双阳;刘杰民;蔺晓源
湖南中医药大学第一附属医院,长沙 410007贵州医科大学,贵阳 561113湖南中医药大学第一附属医院,长沙 410007贵州省人民医院,贵阳 550002湖南中医药大学第一附属医院,长沙 410007
医药卫生
溃疡性结肠炎健脾益肠散TNF-α树突状细胞自噬肌球蛋白样BCL2结合蛋白微管相关蛋白1轻链3-Ⅱ自噬蛋白 5自噬蛋白 7泛素结合蛋白 62大鼠小鼠血清
ulcerative colitisJianpi Yichang SanTNF-αdendritic cellsautophagyBeclin-1LC3-ⅡAtg5Atg7p62/SQSTM1ratsmiceserum
《中药新药与临床药理》 2026 (2)
252-260,9
国家自然科学基金项目(82060850,82460924)湖南省自然科学基金项目(2024JJ9435)湖南省教育厅科学研究重点项目(24A0271)贵州省高层次创新型人才项目(黔科合平台人才[2020]6016-2).
评论